Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,244.40",
    "chg": 25,
    "chgp": "2.05%",
    "dir": 1,
    "prev_price": "1,219.40",
    "mcapval": "99,281.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "16.25 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cipla Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-sell-by-marketsmojo-3917968",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_mojoScore_3917968.png",
        "date": "2026-03-26 10:10:02",
        "description": "Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. While the rating change occurred earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 26 March 2026, providing investors with an up-to-date perspective on the company’s position in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-significant-open-interest-surge-amid-mixed-market-signals-3916495",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3916495.png",
        "date": "2026-03-25 15:00:38",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 14.05% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock recorded a 2.08% gain today, reflecting a complex interplay of bullish and bearish sentiments among traders."
      },
      {
        "title": "Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-significant-open-interest-surge-amid-mixed-market-signals-3916371",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3916371.png",
        "date": "2026-03-25 14:00:29",
        "description": "Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock posted a 2.6% gain today, reflecting a complex interplay of bullish and bearish sentiments among traders."
      },
      {
        "title": "Cipla Ltd Sees Sharp Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-sharp-open-interest-surge-amid-mixed-market-signals-3916271",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3916271.png",
        "date": "2026-03-25 13:00:24",
        "description": "Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, rising by 11.78% to 81,531 contracts. This increase comes alongside a 2.05% gain in the stock price, signalling a complex interplay of market positioning and investor sentiment amid broader sectoral gains and subdued delivery volumes."
      },
      {
        "title": "Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-significant-open-interest-surge-amid-mixed-market-signals-3916186",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3916186.png",
        "date": "2026-03-25 12:00:17",
        "description": "Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.4% surge in open interest in its derivatives segment, signalling increased market activity and shifting investor positioning. Despite the stock trading near its 52-week low and underperforming key moving averages, the recent uptick in open interest and volume suggests a complex interplay of directional bets and hedging strategies among market participants."
      },
      {
        "title": "P/E at 20.75 vs Industry's 31.53: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-as-a-nifty-50-pharmaceutical-giant-3915453",
        "imagepath": "",
        "date": "2026-03-25 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> at 20.75 stands well below the industry average of 31.53, indicating a substantial valuation discount. This divergence suggests that the market is pricing in either a risk premium or concerns about the company's near-term earnings growth relative to its peers. The sector's elevated P/E reflects optimism around pharmaceutical innovation and growth prospects, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> appears to be viewed more cautiously. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</..."
      },
      {
        "title": "Cipla Ltd. Sees Significant Open Interest Surge Amid Bearish Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-significant-open-interest-surge-amid-bearish-market-signals-3910652",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3910652.png",
        "date": "2026-03-24 14:00:24",
        "description": "Cipla Ltd., a large-cap heavyweight in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.2% surge in open interest (OI) in its derivatives segment, signalling a shift in market positioning. Despite this increase, the stock remains close to its 52-week low and continues to underperform its sector peers, raising questions about the directional bets being placed by traders and investors."
      },
      {
        "title": "Cipla Ltd Sees Sharp Open Interest Surge Amid Bearish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-sharp-open-interest-surge-amid-bearish-market-positioning-3910530",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CiplaLtd_oi_spurts_by_underlying_3910530.png",
        "date": "2026-03-24 13:00:20",
        "description": "Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.3% surge in open interest (OI) in its derivatives segment, signalling increased market activity despite the stock trading near its 52-week lows and underperforming its sector peers. This development highlights shifting market positioning and potential directional bets among traders, warranting a closer examination of volume patterns, price action, and broader market context."
      },
      {
        "title": "P/E at 20.77 vs Industry's 31.09: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-sector-dynamics-3909523",
        "imagepath": "",
        "date": "2026-03-24 09:20:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 20.77, considerably below the Pharmaceuticals &amp; Biotechnology industry average of 31.09. This 33% discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the company’s large-cap status with a market capitalisation of approximately ₹1,00,020 crores. The discount may reflect recent earnings pressures or concerns about the sustainability of margins in a competitive sector. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">Previously rated Hold, what is C..."
      }
    ],
    "total": 983,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "09-Dec-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange that its wholly owned subsidiary Cipla (EU) Limited, holding 60% stake in Cipla Pharma Lanka (Private) Limited {Cipla Pharma Lanka), Sri Lanka, has signed an agreement with CitiHealth Imports",
      "source": "NSE",
      "caption": "Cipla Limited - Acquisition",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "21-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 27 Jun 25",
          "dt": "2025-06-27",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cipla Ltd. is Rated Sell by MarketsMOJO

2026-03-26 10:10:02

Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. While the rating change occurred earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 26 March 2026, providing investors with an up-to-date perspective on the company’s position in the Pharmaceuticals & Biotechnology sector.

Read full news article

Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-03-25 15:00:38

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 14.05% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock recorded a 2.08% gain today, reflecting a complex interplay of bullish and bearish sentiments among traders.

Read full news article

Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-03-25 14:00:29

Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock posted a 2.6% gain today, reflecting a complex interplay of bullish and bearish sentiments among traders.

Read full news article

Cipla Ltd Sees Sharp Open Interest Surge Amid Mixed Market Signals

2026-03-25 13:00:24

Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, rising by 11.78% to 81,531 contracts. This increase comes alongside a 2.05% gain in the stock price, signalling a complex interplay of market positioning and investor sentiment amid broader sectoral gains and subdued delivery volumes.

Read full news article

Cipla Ltd Sees Significant Open Interest Surge Amid Mixed Market Signals

2026-03-25 12:00:17

Cipla Ltd., a major player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.4% surge in open interest in its derivatives segment, signalling increased market activity and shifting investor positioning. Despite the stock trading near its 52-week low and underperforming key moving averages, the recent uptick in open interest and volume suggests a complex interplay of directional bets and hedging strategies among market participants.

Read full news article

P/E at 20.75 vs Industry's 31.53: What the Data Shows for Cipla Ltd.

2026-03-25 09:20:55

Valuation Picture: Discount Amid Sector Premiums

The current P/E of Cipla Ltd. at 20.75 stands well below the industry average of 31.53, indicating a substantial valuation discount. This divergence suggests that the market is pricing in either a risk premium or concerns about the company's near-term earnings growth relative to its peers. The sector's elevated P/E reflects optimism around pharmaceutical innovation and growth prospects, yet Cipla Ltd. appears to be viewed more cautiously. Cipla Ltd.Read full news article

Cipla Ltd. Sees Significant Open Interest Surge Amid Bearish Market Signals

2026-03-24 14:00:24

Cipla Ltd., a large-cap heavyweight in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.2% surge in open interest (OI) in its derivatives segment, signalling a shift in market positioning. Despite this increase, the stock remains close to its 52-week low and continues to underperform its sector peers, raising questions about the directional bets being placed by traders and investors.

Read full news article

Cipla Ltd Sees Sharp Open Interest Surge Amid Bearish Market Positioning

2026-03-24 13:00:20

Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.3% surge in open interest (OI) in its derivatives segment, signalling increased market activity despite the stock trading near its 52-week lows and underperforming its sector peers. This development highlights shifting market positioning and potential directional bets among traders, warranting a closer examination of volume patterns, price action, and broader market context.

Read full news article

P/E at 20.77 vs Industry's 31.09: What the Data Shows for Cipla Ltd.

2026-03-24 09:20:40

Valuation Picture: Discount to Industry P/E

Cipla Ltd. trades at a P/E multiple of 20.77, considerably below the Pharmaceuticals & Biotechnology industry average of 31.09. This 33% discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Such a valuation gap is notable given the company’s large-cap status with a market capitalisation of approximately ₹1,00,020 crores. The discount may reflect recent earnings pressures or concerns about the sustainability of margins in a competitive sector. Previously rated Hold, what is C...

Read full news article

View All News